Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 13/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520696 | 0.84 | SLC2A1 (0.45) | DHFRPLK4SLC2A1NTRK1TLR8 | |
| SCHEMBL14520699 | 0.78 | DHFR (0.42) | DHFRPLK4GPR68 | |
| SCHEMBL14520726 | 0.75 | GPR68 (0.40) | DHFRPLK4GPR68 | |
| SCHEMBL14818977 | 0.66 | MEN1 (0.58) | PLK4NTRK1TLR8GPR68 | |
| SCHEMBL4228985 | 0.66 | PLK4 (0.41) | PLK4CHRM4NTRK1GPR68 | |
| SCHEMBL14520706 | 0.65 | DHFR (0.41) | DHFR | |
| SCHEMBL14520703 | 0.64 | MEN1 (0.49) | DHFRPLK4CHRM4 | |
| SCHEMBL19121747 | 0.63 | SKP2 (0.50) | — | |
| SCHEMBL14520701 | 0.63 | DHFR (0.43) | DHFR | |
| SCHEMBL14804663 | 0.61 | SMN1; SMN2 (0.47) | GPR68 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | Ricerca Biosciences, LLC | 2007-04-12 | — | — | US | disclosed |
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | Ricerca Biosciences, LLC | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | LIG3, LIG1, NQO1 | DHFR 171/4885PLK4 2322/4885TLR7 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.